Invirase (saquinavir)
- Region
- 🇪🇺 EU
- Active substance
- saquinavir
- Company
- Roche Registration GmbH
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 23 Jul 2009
- EU approval
- Thu 03 Oct 1996
- Application
- EMEA/H/C/000113
- ATC
- J05AE01
- Official record
- www.ema.europa.eu
Indication
Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fortovase Withdrawn · Roche Registration Ltd.
Follow Invirase
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.